Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adelstein, D. J.
Right arrow Articles by Forastiere, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adelstein, D. J.
Right arrow Articles by Forastiere, A. A.
Journal of Clinical Oncology, Vol 21, Issue 1 (January), 2003: 92-98
© 2003 American Society for Clinical Oncology

An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer

David J. Adelstein, Yi Li, George L. Adams, Henry Wagner, Jr, Julie A. Kish, John F. Ensley, David E. Schuller, Arlene A. Forastiere

From the Cleveland Clinic Foundation, Cleveland; Arthur G. James Cancer Hospital, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; Fairview University Medical Center (University of Minnesota), Minneapolis, MN; H. Lee Moffitt Cancer Center, Tampa, FL; Henry Ford Hospital, and Karmanos Cancer Institute, Wayne State University, Detroit, MI; and Johns Hopkins University, Baltimore, MD.

Address reprint requests to David J. Adelstein, MD, The Cleveland Clinic Foundation, Department of Hematology and Medical Oncology, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195; email: adelstd{at}ccf.org.

Purpose: The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer.

Patients and Methods: Eligible patients were randomly assigned between arm A (the control), single daily fractionated radiation (70 Gy at 2 Gy/d); arm B, identical radiation therapy with concurrent bolus cisplatin, given on days 1, 22, and 43; and arm C, a split course of single daily fractionated radiation and three cycles of concurrent infusional fluorouracil and bolus cisplatin chemotherapy, 30 Gy given with the first cycle and 30 to 40 Gy given with the third cycle. Surgical resection was encouraged if possible after the second chemotherapy cycle on arm C and, if necessary, as salvage therapy on all three treatment arms. Survival data were compared between each experimental arm and the control arm using a one-sided log-rank test.

Results: Between 1992 and 1999, 295 patients were entered on this trial. This did not meet the accrual goal of 362 patients and resulted in premature study closure. Grade 3 or worse toxicity occurred in 52% of patients enrolled in arm A, compared with 89% enrolled in arm B (P < .0001) and 77% enrolled in arm C (P < .001). With a median follow-up of 41 months, the 3-year projected overall survival for patients enrolled in arm A is 23%, compared with 37% for arm B (P = .014) and 27% for arm C (P = not significant).

Conclusion: The addition of concurrent high-dose, single-agent cisplatin to conventional single daily fractionated radiation significantly improves survival, although it also increases toxicity. The loss of efficacy resulting from split-course radiation was not offset by either multiagent chemotherapy or the possibility of midcourse surgery.

This study was conducted by the Eastern Cooperative Oncology Group (Robert L. Comis, MD, Chair) and supported in part by Public Health Service grants nos. CA23318, CA66636, CA21115, CA04919, CA73590, CA58416, VA14028, CA04920, and CA16116 from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.




This article has been cited by other articles:


Home page
 NEJMHome page
R. I. Haddad and D. M. Shin
Recent Advances in Head and Neck Cancer
N. Engl. J. Med., September 11, 2008; 359(11): 1143 - 1154.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. R. Knab, J. K. Salama, A. Solanki, K. M. Stenson, E. E. Cohen, M. E. Witt, D. J. Haraf, and E. E. Vokes
Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma
Ann. Onc., September 1, 2008; 19(9): 1650 - 1654.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-K. Tai, M.-H. Yang, L.-W. Wang, T.-L. Tsai, P.-Y. Chu, Y.-F. Wang, J.-L. Huang, and S.-Y. Chang
Chemoradiotherapy Laryngeal Preservation for Advanced Hypopharyngeal Cancer
Jpn. J. Clin. Oncol., August 11, 2008; (2008) hyn073v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. K. Ang
Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes
Oncologist, August 1, 2008; 13(8): 899 - 910.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Russo, R. Haddad, M. Posner, and M. Machtay
Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer
Oncologist, August 1, 2008; 13(8): 886 - 898.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. H. Yoo, G. Subramanian, M. P. Piechocki, J. F. Ensley, O. Kucuk, O. E. Tulunay, F. Lonardo, H. Kim, J. Won, T. Stevens, et al.
Effect of Docetaxel on the Surgical Tumor Microenvironment of Head and Neck Cancer in Murine Models
Arch Otolaryngol Head Neck Surg, July 1, 2008; 134(7): 735 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. X. Wang, A. Bao, S. J. Herrera, W. T. Phillips, B. Goins, C. Santoyo, F. R. Miller, and R. A. Otto
Intraoperative 186Re-Liposome Radionuclide Therapy in a Head and Neck Squamous Cell Carcinoma Xenograft Positive Surgical Margin Model
Clin. Cancer Res., June 15, 2008; 14(12): 3975 - 3983.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Brizel, B. A. Murphy, D. I. Rosenthal, K. J. Pandya, S. Gluck, H. E. Brizel, R. F. Meredith, D. Berger, M.-G. Chen, and W. Mendenhall
Phase II Study of Palifermin and Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma
J. Clin. Oncol., May 20, 2008; 26(15): 2489 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
J. A Bonner and J. J Caudell
Combining Radiation with Biological Agents: Focus on the Inhibition of Epidermal Growth Factor Receptor
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 423 - 426.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Bernier, J Bonner, J. B. Vermorken, R.-J. Bensadoun, R. Dummer, J. Giralt, G. Kornek, A. Hartley, R. Mesia, C. Robert, et al.
Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck
Ann. Onc., January 1, 2008; 19(1): 142 - 149.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
N. Choong and E. Vokes
Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer
CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
R. S. Patel, J. Clark, R. Wyten, K. Gao, and C. J. O'Brien
Squamous Cell Carcinoma From an Unknown Head and Neck Primary Site: A "Selective Treatment" Approach
Arch Otolaryngol Head Neck Surg, December 1, 2007; 133(12): 1282 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Glynne-Jones and P. Hoskin
Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?
J. Clin. Oncol., November 20, 2007; 25(33): 5281 - 5286.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. M. Specenier, D. Van den Weyngaert, C. Van Laer, J. Weyler, J. Van den Brande, M. T. Huizing, J. Dyck, D. Schrijvers, and J. B. Vermorken
Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data
Ann. Onc., November 1, 2007; 18(11): 1856 - 1860.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, M. Degardin, J. S. Stewart, S. Jelic, J. Betka, J. H. Preiss, et al.
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
N. Engl. J. Med., October 25, 2007; 357(17): 1695 - 1704.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. R. Posner, D. M. Hershock, C. R. Blajman, E. Mickiewicz, E. Winquist, V. Gorbounova, S. Tjulandin, D. M. Shin, K. Cullen, T. J. Ervin, et al.
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
N. Engl. J. Med., October 25, 2007; 357(17): 1705 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Zenda, Y. Onozawa, M. Tahara, M. Kawashima, N. Shikama, S. Sasaki, and N. Boku
Feasibility Study of Single Agent Cisplatin and Concurrent Radiotherapy in Japanese Patients with Squamous Cell Carcinoma of the Head and Neck: Preliminary Results
Jpn. J. Clin. Oncol., October 8, 2007; (2007) hym106v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. K. Salama, T. Y. Seiwert, and E. E. Vokes
Chemoradiotherapy for Locally Advanced Head and Neck Cancer
J. Clin. Oncol., September 10, 2007; 25(26): 4118 - 4126.
[Full Text] [PDF]

Home page
 JCOHome page
C. L. Zuur, Y. J. Simis, P. E. Lansdaal, A. A. Hart, J. H. Schornagel, W. A. Dreschler, C. R. Rasch, and A. J. Balm
Ototoxicity in a Randomized Phase III Trial of Intra-Arterial Compared With Intravenous Cisplatin Chemoradiation in Patients With Locally Advanced Head and Neck Cancer
J. Clin. Oncol., August 20, 2007; 25(24): 3759 - 3765.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Kawashima, H. Fujii, R. Hayashi, M. Tahara, K. Nasu, S. Arahira, and T. Ogino
Influence of Delayed Tumor Clearance on Reliability of Complete Response Rate in Chemoradiotherapy for Head and Neck Cancer
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym072v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. B. van den Broek, V. B. Wreesmann, M. W.M. van den Brekel, C. R.N. Rasch, A. J.M. Balm, and P. H. Rao
Genetic Abnormalities Associated with Chemoradiation Resistance of Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., August 1, 2007; 13(15): 4386 - 4391.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Posner
Evolving Strategies for Combined-Modality Therapy for Locally Advanced Head and Neck Cancer
Oncologist, August 1, 2007; 12(8): 967 - 974.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Zenda, Y. Onozawa, N. Boku, Y. Iida, M. Ebihara, and T. Onitsuka
Single-agent Docetaxel in Patients with Platinum-refractory Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Jpn. J. Clin. Oncol., July 1, 2007; 37(7): 477 - 481.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Agarwala, E Cano, D. Heron, J Johnson, E Myers, V Sandulache, S Bahri, R Ferris, Y Wang, and A Argiris
Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer
Ann. Onc., July 1, 2007; 18(7): 1224 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Kawashima, R. Hayashi, M. Tahara, M. Yamazaki, M. Miyazaki, S. Arahira, and T. Ogino
Accelerated Radiotherapy and Larynx Preservation in Favorable-risk Patients with T2 or Worse Hypopharyngeal Cancer
Jpn. J. Clin. Oncol., June 21, 2007; (2007) hym040v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Allen and R. B. Tishler
Commentary: IMRT for Head and Neck Cancer: Many Chapters Left to Write
Oncologist, May 1, 2007; 12(5): 565 - 568.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Fuwa, T. Kodaira, H. Tachibana, T. Nakamura, and T. Daimon
Dose Escalation Study of Nedaplatin with 5-Fluorouracil in Combination with Alternating Radiotherapy in Patients with Head and Neck Cancer
Jpn. J. Clin. Oncol., March 1, 2007; 37(3): 161 - 167.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. J. Stiff, C. Emmanouilides, W. I. Bensinger, T. Gentile, B. Blazar, T. C. Shea, J. Lu, J. Isitt, A. Cesano, and R. Spielberger
Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting
J. Clin. Oncol., November 20, 2006; 24(33): 5186 - 5193.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. S. Tsao, A. S. Garden, M. S. Kies, W. Morrison, L. Feng, J. J. Lee, F. Khuri, R. Zinner, J. Myers, V. Papadimitrakopoulou, et al.
Phase I/II Study of Docetaxel, Cisplatin, and Concomitant Boost Radiation for Locally Advanced Squamous Cell Cancer of the Head and Neck
J. Clin. Oncol., September 1, 2006; 24(25): 4163 - 4169.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Forastiere, A. Trotti, D. G. Pfister, and J. R. Grandis
Head and Neck Cancer: Recent Advances and New Standards of Care
J. Clin. Oncol., June 10, 2006; 24(17): 2603 - 2605.
[Full Text] [PDF]

Home page
 JCOHome page
D. M. Brizel and R. Esclamado
Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum
J. Clin. Oncol., June 10, 2006; 24(17): 2612 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Adelstein and M. LeBlanc
Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer?
J. Clin. Oncol., June 10, 2006; 24(17): 2624 - 2628.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bernier, J. B. Vermorken, and W. M. Koch
Adjuvant Therapy in Patients With Resected Poor-Risk Head and Neck Cancer
J. Clin. Oncol., June 10, 2006; 24(17): 2629 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. I. Rosenthal, J. S. Lewin, and A. Eisbruch
Prevention and Treatment of Dysphagia and Aspiration After Chemoradiation for Head and Neck Cancer
J. Clin. Oncol., June 10, 2006; 24(17): 2636 - 2643.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Rischin, R. J. Hicks, R. Fisher, D. Binns, J. Corry, S. Porceddu, and L. J. Peters
Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography-Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02
J. Clin. Oncol., May 1, 2006; 24(13): 2098 - 2104.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
L. A. Goguen, M. R. Posner, R. B. Tishler, L. J. Wirth, C. M. Norris, D. J. Annino, C. A. Sullivan, Y. Li, and R. I. Haddad
Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer.
Arch Otolaryngol Head Neck Surg, May 1, 2006; 132(5): 526 - 531.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. W.T. Alkureishi, R. de Bree, and G. L. Ross
RADPLAT: An Alternative to Surgery?
Oncologist, May 1, 2006; 11(5): 469 - 480.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. A. Conley
Treatment of Advanced Head and Neck Cancer: What Lessons Have We Learned?
J. Clin. Oncol., March 1, 2006; 24(7): 1023 - 1025.
[Full Text] [PDF]

Home page
 JCOHome page
D. J. Adelstein, J. P. Saxton, L. A. Rybicki, R. M. Esclamado, B. G. Wood, M. Strome, P. Lavertu, R. R. Lorenz, and M. A. Carroll
Multiagent Concurrent Chemoradiotherapy for Locoregionally Advanced Squamous Cell Head and Neck Cancer: Mature Results From a Single Institution
J. Clin. Oncol., March 1, 2006; 24(7): 1064 - 1071.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, Y. B. Su, D. H. Kraus, S. L. Wolden, E. Lis, T. B. Aliff, A. J. Zahalsky, S. Lake, M. N. Needle, A. R. Shaha, et al.
Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm
J. Clin. Oncol., March 1, 2006; 24(7): 1072 - 1078.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin, R. B. Cohen, C. U. Jones, R. Sur, D. Raben, J. Jassem, et al.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
N. Engl. J. Med., February 9, 2006; 354(6): 567 - 578.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. R. Posner and L. J. Wirth
Cetuximab and Radiotherapy for Head and Neck Cancer
N. Engl. J. Med., February 9, 2006; 354(6): 634 - 636.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. Merlano
Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative?
Oncologist, February 1, 2006; 11(2): 146 - 151.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Adelstein
Induction Redux: Once More With Taxanes
J. Clin. Oncol., December 1, 2005; 23(34): 8556 - 8558.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Kitamoto, T. Akimoto, H. Ishikawa, T. Nonaka, H. Katoh, T. Nakano, H. Ninomiya, K. Chikamatsu, and N. Furuya
Acute Toxicity and Preliminary Clinical Outcomes of Concurrent Radiation Therapy and Weekly Docetaxel and Daily Cisplatin for Head and Neck Cancer
Jpn. J. Clin. Oncol., November 1, 2005; 35(11): 639 - 644.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Rastogi, M. Srivastava, K. S. Chufal, M. C. Pant, K. Srivastava, and M. B. Bhatt
Mitomycin and Fluorouracil in Combination with Concomitant Radiotherapy: A Potentially Curable Approach for Locally Advanced Head and Neck Squamous Cell Carcinoma
Jpn. J. Clin. Oncol., October 1, 2005; 35(10): 572 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
T. Ayad, M. Gelinas, L. Guertin, D. Larochelle, P. Del Vecchio, J.-C. Tabet, M.-J. Olivier, D. Soulieres, D. Charpentier, and P. F. Nguyen-Tan
Retromolar Trigone Carcinoma Treated by Primary Radiation Therapy: An Alternative to the Primary Surgical Approach
Arch Otolaryngol Head Neck Surg, July 1, 2005; 131(7): 576 - 582.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. K. Ang, J. Harris, A. S. Garden, A. Trotti, C. U. Jones, L. Carrascosa, J. D. Cheng, S. S. Spencer, A. Forastiere, and R. S. Weber
Concomitant Boost Radiation Plus Concurrent Cisplatin for Advanced Head and Neck Carcinomas: Radiation Therapy Oncology Group Phase II Trial 99-14
J. Clin. Oncol., May 1, 2005; 23(13): 3008 - 3015.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
G. H. Yoo, G. Subramanian, R. R. Boinpally, A. Iskander, N. Shehadeh, J. Oliver, W. Ezzat, M. P. Piechocki, J. F. Ensley, H.-S. Lin, et al.
An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma
Arch Otolaryngol Head Neck Surg, May 1, 2005; 131(5): 418 - 429.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. T. Robbins, P. Kumar, J. Harris, T. McCulloch, A. Cmelak, R. Sofferman, P. Levine, R. Weisman, W. Wilson, E. Weymuller, et al.
Supradose Intra-Arterial Cisplatin and Concurrent Radiation Therapy for the Treatment of Stage IV Head and Neck Squamous Cell Carcinoma Is Feasible and Efficacious in a Multi-Institutional Setting: Results of Radiation Therapy Oncology Group Trial 9615
J. Clin. Oncol., March 1, 2005; 23(7): 1447 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. R. Posner
Adjuvant Post-Operative Chemoradiotherapy In Head and Neck Cancer: A Standard Of Care?
Oncologist, March 1, 2005; 10(3): 174 - 175.
[Full Text] [PDF]

Home page
 JCOHome page
D. Rischin, L. Peters, R. Fisher, A. Macann, J. Denham, M. Poulsen, M. Jackson, L. Kenny, M. Penniment, J. Corry, et al.
Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)
J. Clin. Oncol., January 1, 2005; 23(1): 79 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Vokes
Current treatments and promising investigations in a multidisciplinary setting
Ann. Onc., January 1, 2005; 16(suppl_6): vi25 - vi30.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. K. Ang
Concurrent Radiation Chemotherapy for Locally Advanced Head and Neck Carcinoma: Are We Addressing Burning Subjects?
J. Clin. Oncol., December 1, 2004; 22(23): 4657 - 4659.
[Full Text] [PDF]